Brachet G, Bourquard T, Gallay N, Reiter E, Gouilleux-Gruart V, Poupon A, Watier H (2016) Eculizumab epitope on complement C5: progress towards a better understanding of the mechanism of action. Mol Immunol 77:126-131. doi:10.1016/j.molimm.2016. 07.016...
Eculizumab's mechanism of action involves binding to a specific protein called complement protein C5 in the blood, preventing it from breaking apart into other proteins that can destroy red blood cells. Eculizumab is used to treat people with genetic conditions that affect the natural defenses of ...
Mechanism of Action? Pharmacodynamics? Pharmacokinetics? NONCLINICAL TOXICOLOGY? Carcinogenesis, Mutagenesis, Impairment of Fertility? CLINICAL STUDIES? PNH? aHUS? HOW SUPPLIED/STORAGE AND HANDLING? PATIENT COUNSELING INFORMATION? *Sections or subsections omitted from the full prescribing information are not ...
Eculizumab is a monoclonal antibody that specifically binds to the complement protein C5, inhibiting its cleavage into C5a and C5b and preventing the formation of the membrane attack complex (MAC). This mechanism of action plays a crucial role in the treatment of PNH and aHUS, providing ...
ATG is commonly used for conditioning, especially in nonmalignant diseases, to facilitate engraftment and to mitigate GVHD; its mechanism of action is both complement dependent and independent [2]. One could hypothesize that the blockage of terminal complement by eculizumab could predispose to or ...
The failure of eculizumab to affect erythrocyte agglutination was expected and in keeping with its mechanism of action, which targets complement activation and not erythrocyte cross-linking by IgM autoantibodies. The patient with the acute CAS experienced severe exacerbation of intravascular hemolysis after...
Mechanism Of Action Eculizumab-aeeb, the active ingredient in BKEMV, is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Eculizumab...
12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Paroxysmal Nocturnal Hemoglobinuria (PNH) 14.2 Atypical Hemolytic Uremic Syndrome (aHUS) ...
treatment with adequateCtroughlevels. Besides discordant results between different assays used in the clinics, remaining hemolytic activity could persist in light of strong complement activation [76]. Careful characterization and monitoring of these patients is necessary to understand this mechanism [76]. ...
Our work outlines a general strategy for stratification of responders and non-responders for treatment with therapeutic antibodies and more specifically analyses the underlying molecular mechanism for patients’ response to the therapeutic antibody eculizumab. Figure 1 Generation and sorting of the ...